BioSpace News Archive

Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders.

Two abstracts include data generated in collaboration with Eli Lilly and Company and focusing on an AI-driven automated disease scoring technology aimed to accelerate clinical trials for ulcerative colitis.

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a conditional marketing authorisation for Kinpeygo TM.

LumiraDx Limited, a next-generation point of care diagnostics company, announced its SARS-CoV-2 Ag Ultra Test achieved CE Marking.

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today its financial results for the quarter ending March 31, 2022, and provided an overview of recent operational highlights.

Electromed, Inc. announced the results of a third-party, clinical study presented as a clinical abstract poster at the American Thoracic Society International Conference in San Francisco, CA.

Adhera Therapeutics, Inc. is pleased to announce the appointment of Trond K. Waerness as Chairman of the Company’s Board of Directors.

Thermo Fisher Scientific Inc., the world leader in serving science, announced that on May 18, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on July 15, 2022, to shareholders of record as of June 15, 2022.

Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company’s latest-generation transcatheter aortic valve implantation (TAVI) system.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with antihistamine refractory chronic spontaneous urticaria (CSU), has been accepted as a late-breaking electronic poster presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022.